Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1649 1675
This examiner grants 58% of resolved cases
Selam Berhane serves as an examiner in Tech Center 1600, working within Art Unit 1643. The examiner has a record of 89 resolved cases, providing a dataset for analysis. The allowance rate is 58.4 percent, indicating the frequency with which applications reach a grant. This 58.4 percent rate serves as the primary baseline for assessing prosecution risk on this docket. The 89 resolved cases establish the current statistical record for this examiner.
The interview lift is 56.7 percent, which is a high value compared to the baseline. This 56.7 percent lift suggests that conducting an interview is an effective strategy for improving the chances of an allowance. When compared to the 58.4 percent allowance rate, the benefit of direct engagement is clear. The median days to allowance is 1311, representing the typical timeframe for applications that successfully navigate the process. This 1311 median days to allowance helps set expectations for the overall timeline.
The data in Art Unit 1643 shows that the interview lift is 56.7 percent, highlighting the importance of oral advocacy. The 1311 median days to allowance provides a benchmark for pendency in Tech Center 1600. The 58.4 percent allowance rate remains a key metric for evaluating the likelihood of a grant. These figures provide a data-driven basis for a proactive prosecution strategy before this examiner and managing client expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258758 | AMYLOID-SPECIFIC ANTIBODIES AND USES THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17635111 | CHIMERIC ANTIGEN RECEPTORS FOR TREATING MYELOID MALIGNANCIES | Final Rejection | Regents of the University of Minnesota |
| 18173680 | Compositions and Methods for Killing PD-1 Positive Cells | Final Rejection | University of Utah Research Foundation |
| 18499540 | ANTICANCER THERAPIES USING ANTI-CCR8 ANTIBODY, CHEMO AND IMMUNOTHERAPY COMBINATIONS | Non-Final OA | Gilead Sciences, Inc. |
| 17771353 | CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS | Final Rejection | NOVARTIS AG |
| 18566564 | METHODS AND COMPOSITIONS FOR LOCALIZATION OF GROWTH FACTORS | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 17778375 | BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH ENHANCED CYTOTOXIC EFFECTS ON TUMOR CELLS | Non-Final OA | Brown University |
| 17616941 | TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL RESPONSES | Final Rejection | Oregon Health & Science University |
| 17259800 | METHODS OF USING PHARMACOLOGIC INHIBITORS OF TYPE 2 CYTOKINE SIGNALING TO TREAT OR PREVENT PANCREATIC CANCER | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 17843812 | ANTI-TGF-BETA ANTIBODY FORMULATIONS AND THEIR USE | Final Rejection | Genzyme Corporation |
| 18281161 | NOVEL DARPIN BASED CD123 ENGAGERS | Non-Final OA | MOLECULAR PARTNERS AG |
| 18028200 | HUMANIZED ANTI-CD22 RECOMBINANT IMMUNOTOXIN AND APPLICATION THEREOF | Final Rejection | KUNMING SINOWAY NATURAL PHARMACEUTICALS CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy